Abstract 3364
Background
RAS mutational status is an essential criterion to guide first-line treatment in metastatic colorectal cancer (mCRC). MORE-RAS was a multicenter, multicountry, observational, ambispective (retrospective + prospective) study conducted in the Middle East and North Africa (MENA) region to assess RAS testing practices and tumor characteristics in newly diagnosed patients (pts) with mCRC. Results of the retrospective analysis are presented here.
Methods
Eligible pts included adults aged ≥18 with mCRC who had already initiated first-line therapy, had at least 1 post-baseline visit for disease evaluation, and had available survival data. Pts with incomplete and unavailable data or presence of other coexisting malignancies were excluded. Data from eligible pts were retrospectively analysed 2 years back from the day of patient consent.
Results
A total of 495 pts (median age: 57 y) were enrolled; majority were male (55.6%), with adenocarcinoma histology, stage IV disease (86.8%) and left-sided tumors (79%). Primary tumor site was sigmoid (40.9%), followed by rectal (26.1%), ascending (17.2%), descending (12.1%), and transverse (3.8%) colon. RAS testing was requested in 417 (78%) pts; reasons for not prescribing included test unavailability, financial/medical decision, or other. Testing samples were mostly paraffin-embedded (91.7%) primary tumors (92.5%); sequencing was the most common test method used. RAS testing found that 33.9% of tumors harbored mutations and 66.1% carried wild-type (WT) sequences. The most common mutation was KRAS (94.1%), occurring largely in Exon2-Codon12 (70.5%). RAS testing was typically prescribed after initiation of first-line treatment, significantly more in pts with stage IV disease (p < 0.005), resulted in addition of targeted therapy (41.8% anti EGFR, 30.2% anti VEGF) in WT mCRC, and significantly impacted treatment strategy of left-sided tumors (p = 0.037).
Conclusions
RAS testing for mCRC in the MENA region was often performed after first-line treatment. The dominance of WT RAS in this region is distinct from the mutational pattern reported in Western countries.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Amgen.
Funding
Amgen.
Disclosure
M. Oukkal: Advisory / Consultancy, Speaker Bureau / Expert testimony: Amgen; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Roche; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pfizer; Speaker Bureau / Expert testimony: Bayer; Speaker Bureau / Expert testimony: Ipsen. H. Mahfouf: Advisory / Consultancy, Speaker Bureau / Expert testimony: Amgen; Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck; Advisory / Consultancy, Speaker Bureau / Expert testimony: Bayer; Advisory / Consultancy: Ipsen. A. Ouamer: Full / Part-time employment: Amgen. L. Bashir: Full / Part-time employment: Amgen. All other authors have declared no conflicts of interest.
Resources from the same session
2551 - Efficacy of dose-dense (DD) adjuvant chemotherapy (CT) in hormone receptor positive/HER2-negative early breast cancer (BC) patients (pts) according to immunohistochemically (IHC) defined luminal subtypes: an exploratory analysis of the GIM2 trial.
Presenter: Benedetta Conte
Session: Poster Display session 2
Resources:
Abstract
3426 - High dose Neo-adjuvant chemotherapy in Triple-Negative breast cancer with evidence of homologous recombination deficiency (HRD).
Presenter: Sonja Vliek
Session: Poster Display session 2
Resources:
Abstract
3792 - Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: pooled analysis of prospective neoadjuvant breast cancer (BC) trials
Presenter: Gustavo Werutsky
Session: Poster Display session 2
Resources:
Abstract
4044 - Estimating radiotherapy-induced cardiovascular mortality in female breast cancer patients.
Presenter: Mark De Ridder
Session: Poster Display session 2
Resources:
Abstract
719 - 3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC)
Presenter: Justin Stebbing
Session: Poster Display session 2
Resources:
Abstract
3595 - Adjuvant chemotherapy in elderly breast cancer patients: pattern of use and impact on overall survival
Presenter: Axel Berthelot
Session: Poster Display session 2
Resources:
Abstract
3992 - Carboplatin-containing neoadjuvant chemotherapy for triple negative breast cancer (TNBC): a propensity score-matched study.
Presenter: Maria Vittoria Dieci
Session: Poster Display session 2
Resources:
Abstract
3477 - Impact of adjuvant trastuzumab emtansine (T-DM1) on incidence of metastatic breast cancer (mBC): an epidemiological model of patients with HER2-positive breast cancer (BC) who did not achieve pathological complete response (pCR) after neoadjuvant treatment (non-pCR)
Presenter: Mellissa Williamson
Session: Poster Display session 2
Resources:
Abstract
3928 - Chemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: Results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study
Presenter: Hans Tesch
Session: Poster Display session 2
Resources:
Abstract
2184 - The clinical impact of adjuvant dose-dense sequential chemotherapy (dds-CT) in patients with high-risk operable breast cancer (BC); pooled analysis of 6 clinical trials.
Presenter: Elena Fountzilas
Session: Poster Display session 2
Resources:
Abstract